Comprehensive Guide to IPF: Therapies, Treatments & Management Strategies
- Treatment for idiopathic pulmonary fibrosis (IPF) focuses on slowing the progression of lung scarring, managing debilitating symptoms, and improving the overall quality of life for patients.
- Care typically begins immediately following a confirmed diagnosis.
- Antifibrotic drugs serve as the primary pharmacological treatment for IPF.
Treatment for idiopathic pulmonary fibrosis (IPF) focuses on slowing the progression of lung scarring, managing debilitating symptoms, and improving the overall quality of life for patients. While current medical interventions cannot reverse the fibrosis that has already occurred, a combination of pharmaceutical, therapeutic, and surgical options can help preserve lung function.
Care typically begins immediately following a confirmed diagnosis. Medical teams determine the specific treatment plan based on the severity of the disease, the rate of progression, the patient’s current symptoms, and their general health status.
Antifibrotic Medications and Disease Management
Antifibrotic drugs serve as the primary pharmacological treatment for IPF. Rather than repairing existing damage, these medications aim to slow the rate at which the lungs build scar tissue.
There are currently three FDA-approved antifibrotic options administered orally: nintedanib (Ofev), pirfenidone (Esbriet), and nerandomilast (Jascayd). Nerandomilast, which received FDA approval in 2025, represents the first new treatment for the condition in over a decade.
According to Dr. Kenneth D’Souza, a pulmonologist and medical director of the intensive care unit at Mercy Health in Cincinnati, nerandomilast operates through a different mechanism than previous antifibrotics. It is generally utilized as an alternative for patients who cannot tolerate nintedanib or pirfenidone.
These medications can cause various side effects, including nausea, vomiting, diarrhea, fatigue, headache, dizziness, and elevated liver enzymes. Patients using pirfenidone may also experience skin rashes or increased sun sensitivity, requiring additional skin protection.
Supportive Pharmacological Treatments
Beyond antifibrotics, healthcare providers may prescribe other medications to manage specific complications associated with IPF.
Corticosteroids, such as prednisone and methylprednisolone, are sometimes used to reduce lung inflammation during acute exacerbations, or flare-ups. Because evidence regarding their long-term impact on outcomes is limited, these are typically reserved for short-term use.
Many patients with IPF also suffer from gastroesophageal reflux disease (GERD). When stomach acid is inhaled into the lungs, it can irritate lung tissue and worsen coughing and shortness of breath. Medications such as omeprazole, esomeprazole, and famotidine are used to manage GERD symptoms to prevent this irritation.
To address the persistent dry cough common in IPF, doctors may recommend suppressants like dextromethorphan or benzonatate, though effectiveness varies by individual.
Rehabilitation and Oxygen Therapy
Non-pharmacological therapies are essential for maintaining mobility and improving breathing efficiency.
Supplemental oxygen is often recommended when oxygen levels drop below 88 percent during rest or physical activity. This need is frequently identified using a six-minute walk test, which monitors breathing and oxygen saturation during movement.
Depending on the patient’s needs, oxygen may be required only during sleep or exercise, or on a more regular basis. Portable oxygen systems are available to help patients maintain their daily activities.
Pulmonary rehabilitation is another key component of care. This supervised program integrates exercise, breathing techniques, and disease education. Dr. D’Souza notes that these programs can increase a patient’s ability to remain physically active and reduce the sensation of shortness of breath.
Dr. Guillermo Garrido, a board-certified physician with Orlando Health Medical Group Pulmonary and Sleep Medicine, states that pulmonary rehab can benefit nearly anyone whose quality of life has been impacted by IPF. He also notes that it is an effective way to improve physical readiness for those considering a lung transplant.
Surgical Options and Lung Transplantation
A lung transplant is the only surgical treatment available for IPF, involving the replacement of diseased lungs with healthy donor lungs. While it can offer more time and improved quality of life, it is a major procedure with significant risks, including infection and organ rejection.
Post-transplant care requires lifelong medication to prevent rejection.
Guidelines recommend transplant evaluation as soon as an [IPF] diagnosis is made,
Dr. Guillermo Garrido
Early evaluation allows patients to understand the risks and benefits before the disease progresses further. The evaluation process is comprehensive, reviewing physical fitness, heart, kidney, and liver function, bone health, emotional readiness, and the availability of social support for post-surgical care.
Transplant candidates are typically younger than 70 and generally healthy outside of their lung disease, although these criteria can be flexible.
Holistic Care and Lifestyle Adjustments
Managing the mental and physical aspects of a chronic condition is vital for overall well-being. Anxiety and depression are common among those living with IPF due to changes in mobility and the effort required to manage symptoms.
Medical professionals suggest working with mental health specialists, practicing mindfulness meditation, or engaging in yoga to cope with stress and shortness of breath. Support groups and specific breathing exercises are also recommended.
While lifestyle changes cannot reverse fibrosis, they can protect remaining lung health. Experts recommend the following:
- Complete cessation of smoking, including vaping and marijuana.
- Staying current on flu and pneumonia vaccinations to lower the risk of respiratory infections.
- Maintaining regular light exercise, such as walking, to improve stamina.
- Managing weight and eating a balanced diet to support energy levels.
- Limiting exposure to environmental irritants like dust, fumes, and pollution.
- Managing comorbid conditions such as diabetes, heart disease, or sleep apnea.
Clinical Trials and Future Outlook
Ongoing research continues to seek new ways to treat IPF. Clinical trials are currently being conducted by major medical centers, the National Institutes of Health, and the Pulmonary Fibrosis Foundation.
Current studies are exploring inhaled therapies and combination drug treatments that target different stages of the scarring process. Dr. Garrido anticipates further innovations in the coming years as research progresses.